Abstract Background Antiseizure drugs (ASDs) are the primary therapy for epilepsy, with
more than 20 drugs introduced into clinical practice to date. These drugs are typically …

Introduction: There are over twenty anti-seizure medications and anti-seizure devices
available commercially in the United States. The multitude of treatment options for seizures …

Objective To update the 2004 American Academy of Neurology guideline for managing
treatment-resistant (TR) epilepsy with second-and third-generation antiepileptic drugs …

Objective To evaluate the efficacy and safety of adjunctive cenobamate 200 mg/d in patients
with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic …

Background More than a third of patients with epilepsy are treatment resistant, and thus new,
more effective therapies to achieve seizure freedom are needed. Cenobamate (YKP3089) …

Objective Brivaracetam (BRV), a selective and high‐affinity synaptic vesicle protein 2A
ligand, is in development as adjunctive treatment for partial‐onset (focal) seizures (POS) …

Drug-resistant epilepsy occurs in 25–30% of patients. Furthermore, treatment with a first-
generation antiseizure drug (ASD) fails in 30–40% of individuals because of their intolerable …

Objective This study was undertaken to evaluate how the challenges in the recruitment and
retention of participants in clinical trials for focal onset epilepsy have changed over time …

Despite the current availability in the market of over two dozen antiepileptic drugs (AEDs),
about one third of people with epilepsy fail to achieve complete freedom from seizures with …

Well‐designed placebo‐controlled clinical trials are critical to the development of novel
treatments for epilepsy, but their design has not changed for decades. Patients, clinicians …